Rocket Pharmaceuticals, Inc. Common Stock (RCKT)
Rocket Pharmaceuticals, Inc. is a clinical-stage company focused on developing innovative gene therapies for rare pediatric diseases. Founded in 2015 and based in New York, the company leverages its platform to develop treatments aimed at addressing the underlying genetic causes of severe, often life-threatening conditions in children. Rocket Pharmaceuticals emphasizes a multidisciplinary approach, combining gene therapy, gene editing, and cellular therapy technologies to deliver potential cures for rare disorders.
Company News
Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.
Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.
Amid market volatility, insiders have been rapidly buying shares in GameStop, Hallador Energy, and Rocket Pharmaceuticals, likely due to their positive outlook on the companies' prospects.
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.